GENNEX LABORATORIES
|
|
BOM : 531739     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : NA |
May 31,2023 |
Price(EOD): βΉ 6.93
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 124.05 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GENNEX LABORATORIES | 4.4% | 12.9% | 3.1% |
SUN PHARMACEUTICAL INDUSTRIES | 3.4% | 0.4% | 6.5% |
DIVIS LABORATORIES | 0.5% | 6.1% | 0.3% |
CIPLA | 1% | 4.2% | -0.5% |
DR REDDYS LABORATORIES | 0% | -9.1% | 5% |
TORRENT PHARMACEUTICALS | 8.4% | 11.4% | 18.2% |
ABBOTT INDIA | -0.5% | -3% | 24.7% |
ZYDUS LIFESCIENCES | -0.7% | -2.8% | 35.6% |
ALKEM LABORATORIES | 1% | -4.3% | 11.1% |
FUNDAMENTAL ANALYSIS OF GENNEX LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GENNEX LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
33.76
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3.67 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] 2.83
P/B Calculated based on Book Value of Rs 43.82 Cr
[Latest Year - Mar2022 - Consolidated Results ] 1.91
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 64.87 Cr
[Latest Qtr - Dec2022 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
47% 52% 53% |
SHARE PRICE MOMENTUM OF GENNEX LABORATORIES
GENNEX LABORATORIES vs SENSEX
DEBT OF GENNEX LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.23 0.18 0.14 0.18 |
0.23 0.19 0.14 0.19 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GENNEX LABORATORIES
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GENNEX LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-25.48% -1.73% 3.65% 3.63% |
2.32% -6.33% -3.59% -1.81% |
QtrlyTrend |
-2 | |
Latest Qtr: Dec2022 | ||
Quarterly Result Analysis → |
GENNEX LABORATORIES related INDICES
You may also like the below Video Courses
FAQ about GENNEX LABORATORIES
Is GENNEX LABORATORIES good for long term investment?
As on May 31,2023, the Fundamentals of GENNEX LABORATORIES look Poor and hence it may not be good for long term investment ! See Financial Performance of GENNEX LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GENNEX LABORATORIES UnderValued or OverValued?
As on May 31,2023, GENNEX LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GENNEX LABORATORIES ?
As on May 31,2023, the Intrinsic Value of GENNEX LABORATORIES is Rs. 4.57 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 4.73
Fair Value [Median EV / Sales Model] : Rs. 4.57
Fair Value [Median Price / Sales Model] : Rs. 4.52
Estimated Median Fair Value of GENNEX LABORATORIES : Rs. 4.57
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is GENNEX LABORATORIES trading at a Premium or Discount?
As on May 31,2023, GENNEX LABORATORIES is trading at a Premium of 52% based on the estimates of Median Intrinsic Value!